{"id":"interferon-alpha2a","safety":{"commonSideEffects":[{"rate":"80-90","effect":"Flu-like symptoms (fever, chills, fatigue)"},{"rate":"70","effect":"Headache"},{"rate":"60-75","effect":"Myalgia"},{"rate":"50-70","effect":"Leukopenia"},{"rate":"30-50","effect":"Thrombocytopenia"},{"rate":"30-40","effect":"Anemia"},{"rate":"20-30","effect":"Depression/mood changes"},{"rate":"10-20","effect":"Thyroid dysfunction"},{"rate":"5-15","effect":"Autoimmune phenomena"}]},"_chembl":{"chemblId":"CHEMBL2108506","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon-alpha2a is a cytokine that binds to type I interferon receptors (IFNAR1/IFNAR2) on cell surfaces, triggering JAK-STAT signaling pathways. This activation enhances natural killer cell and cytotoxic T lymphocyte activity, increases antigen presentation, and induces apoptosis in tumor cells. It also has direct antiproliferative and antiangiogenic effects on malignant cells.","oneSentence":"Interferon-alpha2a activates the innate immune system by binding to interferon-alpha receptors on immune cells and tumor cells, enhancing antiviral and anti-tumor immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:25.688Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Chronic myeloid leukemia (CML)"},{"name":"Follicular lymphoma"},{"name":"Hepatitis C virus infection"}]},"trialDetails":[{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Essential Thrombocythemia","enrollment":340},{"nctId":"NCT05799612","phase":"PHASE1","title":"Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-22","conditions":"Angiosarcoma","enrollment":""},{"nctId":"NCT02743182","phase":"NA","title":"HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients","status":"COMPLETED","sponsor":"José Antonio Carrion","startDate":"2015-01","conditions":"Chronic Hepatitis B (HBeAg-negative)","enrollment":119},{"nctId":"NCT04980482","phase":"PHASE2","title":"Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Arbutus Biopharma Corporation","startDate":"2021-10-29","conditions":"Chronic Hepatitis b","enrollment":43},{"nctId":"NCT02201459","phase":"PHASE3","title":"Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-08","conditions":"Chronic Myeloid Leukemia","enrollment":200},{"nctId":"NCT04439539","phase":"PHASE2","title":"A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-14","conditions":"Hepatitis B, Chronic","enrollment":54},{"nctId":"NCT05756166","phase":"PHASE1, PHASE2","title":"Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-02-16","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma","enrollment":5},{"nctId":"NCT04585789","phase":"PHASE2","title":"A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-11","conditions":"Hepatitis B","enrollment":24},{"nctId":"NCT05535764","phase":"PHASE1","title":"Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-08-02","conditions":"Myelofibrosis","enrollment":18},{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":138},{"nctId":"NCT05683548","phase":"","title":"Replicor Compassionate Access Program","status":"NO_LONGER_AVAILABLE","sponsor":"Replicor Inc.","startDate":"","conditions":"Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver","enrollment":""},{"nctId":"NCT02259855","phase":"PHASE1","title":"Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01-01","conditions":"Hepatic Insufficiency","enrollment":36},{"nctId":"NCT00452023","phase":"PHASE2","title":"Pegasys® in Patients With Myeloproliferative Diseases","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-04-07","conditions":"Myeloproliferative Disorders","enrollment":83},{"nctId":"NCT04116502","phase":"PHASE3","title":"MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-10-25","conditions":"Polycythemia Vera","enrollment":586},{"nctId":"NCT03852433","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-05-31","conditions":"Chronic Hepatitis Delta","enrollment":175},{"nctId":"NCT04412863","phase":"PHASE2","title":"Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Vir Biotechnology, Inc.","startDate":"2020-07-03","conditions":"Chronic Hepatitis B","enrollment":84},{"nctId":"NCT06471673","phase":"PHASE1, PHASE2","title":"A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2024-05-29","conditions":"Breast Cancer, Breast Tumor, Cancer of Breast","enrollment":18},{"nctId":"NCT05244057","phase":"PHASE2","title":"A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2022-08-23","conditions":"Chronic Hepatitis B","enrollment":8},{"nctId":"NCT04667104","phase":"PHASE2","title":"A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-02-01","conditions":"Hepatitis B, Chronic","enrollment":48},{"nctId":"NCT05005507","phase":"PHASE2","title":"A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-11-03","conditions":"Hepatitis B, Chronic","enrollment":1},{"nctId":"NCT02471430","phase":"PHASE1, PHASE2","title":"Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2016-05","conditions":"HIV Infection","enrollment":17},{"nctId":"NCT01120795","phase":"PHASE4","title":"Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy","status":"COMPLETED","sponsor":"Melbourne Health","startDate":"2004-02","conditions":"Chronic Hepatitis C","enrollment":55},{"nctId":"NCT00002965","phase":"PHASE2","title":"Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1997-01","conditions":"Brain and Central Nervous System Tumors","enrollment":16},{"nctId":"NCT00882193","phase":"EARLY_PHASE1","title":"Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-05-01","conditions":"Chronic Hepatitis C, Genotype 1, Relapse","enrollment":2},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT02992457","phase":"PHASE4","title":"Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection","status":"COMPLETED","sponsor":"Tanta University","startDate":"2015-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT04798612","phase":"PHASE2","title":"Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression","status":"UNKNOWN","sponsor":"Zealand University Hospital","startDate":"2023-08-14","conditions":"Colon Cancer","enrollment":68},{"nctId":"NCT02340962","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2015-05","conditions":"Hepatitis C, Chronic","enrollment":25},{"nctId":"NCT03771677","phase":"NA","title":"To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-12-01","conditions":"Hepatitis B","enrollment":400},{"nctId":"NCT01369212","phase":"PHASE3","title":"Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2012-11","conditions":"Hepatitis B","enrollment":201},{"nctId":"NCT03719313","phase":"PHASE3","title":"Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2018-12-01","conditions":"Hepatitis Delta Virus","enrollment":407},{"nctId":"NCT02430194","phase":"PHASE2","title":"Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2014-12","conditions":"Chronic Hepatitis D Infection","enrollment":55},{"nctId":"NCT02087111","phase":"PHASE4","title":"Telaprevir in Genotype 3 HCV","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-04","conditions":"Hepatitis C","enrollment":14},{"nctId":"NCT01519960","phase":"PHASE3","title":"A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-07-11","conditions":"Hepatitis B, Chronic","enrollment":165},{"nctId":"NCT04365933","phase":"PHASE2","title":"A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir","status":"COMPLETED","sponsor":"Enyo Pharma","startDate":"2020-05-25","conditions":"Hepatitis B, Chronic","enrollment":20},{"nctId":"NCT02742324","phase":"PHASE1, PHASE2","title":"Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2016-03","conditions":"Myelofibrosis","enrollment":37},{"nctId":"NCT04522557","phase":"PHASE1","title":"Type I Interferon Alfa-2a in Postmastectomy Breast Reconstruction","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2020-08-06","conditions":"Breast Neoplasms","enrollment":21},{"nctId":"NCT00078403","phase":"PHASE2","title":"Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections, Hepatitis C, Liver Disease","enrollment":333},{"nctId":"NCT00000754","phase":"PHASE2","title":"A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT00991289","phase":"PHASE2","title":"Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-01","conditions":"HIV Infection, Hepatitis C Infection","enrollment":68},{"nctId":"NCT00001113","phase":"PHASE1","title":"A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Sarcoma, Kaposi, HIV Infections","enrollment":48},{"nctId":"NCT00000725","phase":"PHASE1","title":"A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Sarcoma, Kaposi, HIV Infections","enrollment":56},{"nctId":"NCT00000687","phase":"PHASE2","title":"Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Sarcoma, Kaposi, HIV Infections","enrollment":60},{"nctId":"NCT00000696","phase":"PHASE1","title":"A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT00051077","phase":"PHASE2","title":"Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B, Hepatitis C","enrollment":""},{"nctId":"NCT00100581","phase":"NA","title":"Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":2},{"nctId":"NCT00008463","phase":"PHASE2","title":"A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-11","conditions":"HIV Infections, Hepatitis C","enrollment":132},{"nctId":"NCT00000967","phase":"PHASE1","title":"The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":52},{"nctId":"NCT00000764","phase":"PHASE1","title":"Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Anus Neoplasms","enrollment":98},{"nctId":"NCT01185028","phase":"PHASE1, PHASE2","title":"A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2010-08","conditions":"Hepatitis C Infection, HIV Infection","enrollment":8},{"nctId":"NCT00381953","phase":"PHASE3","title":"High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2003-02","conditions":"Hepatitis C","enrollment":33},{"nctId":"NCT03480932","phase":"PHASE2, PHASE3","title":"Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-02-02","conditions":"Hepatitis C, Chronic","enrollment":150},{"nctId":"NCT02541409","phase":"PHASE2","title":"Directly Observed Therapy for HCV in Chennai, India","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2015-09","conditions":"Hepatitis C, Chronic","enrollment":50},{"nctId":"NCT04072263","phase":"PHASE1, PHASE2","title":"Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2018-08-01","conditions":"Ovarian Cancer Recurrent","enrollment":12},{"nctId":"NCT00973219","phase":"NA","title":"Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2009-09","conditions":"Chronic Hepatitis B","enrollment":151},{"nctId":"NCT03209219","phase":"PHASE3","title":"Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2017-06-30","conditions":"Behçet Disease, Uveitis","enrollment":28},{"nctId":"NCT00943761","phase":"PHASE2","title":"A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10-23","conditions":"Hepatitis C, Chronic","enrollment":45},{"nctId":"NCT01821963","phase":"PHASE3","title":"Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-04","conditions":"Infection","enrollment":1},{"nctId":"NCT02263079","phase":"PHASE3","title":"A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-06-16","conditions":"Pediatric Immuno-Tolerant Chronic Hepatitis B","enrollment":62},{"nctId":"NCT00166296","phase":"PHASE2","title":"Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-03","conditions":"Major Depressive Disorder, Hepatitis C, Chronic","enrollment":133},{"nctId":"NCT00845676","phase":"PHASE4","title":"Treatment of Acute Hepatitis C Virus in HIV Co-Infection","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-03","conditions":"Hepatitis C, Human Immunodeficiency Virus, HIV Infections","enrollment":21},{"nctId":"NCT02174172","phase":"PHASE1","title":"A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-08-18","conditions":"Solid Cancers","enrollment":158},{"nctId":"NCT00006164","phase":"PHASE3","title":"Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2000-06","conditions":"Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver","enrollment":1050},{"nctId":"NCT00219739","phase":"PHASE3","title":"STI571 ProspectIve RandomIzed Trial: SPIRIT","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2003-09","conditions":"Chronic Myeloid Leukemia","enrollment":789},{"nctId":"NCT01524679","phase":"PHASE2","title":"Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen","status":"COMPLETED","sponsor":"Johannes Gutenberg University Mainz","startDate":"2012-08","conditions":"Chronic Hepatitis B","enrollment":170},{"nctId":"NCT03957629","phase":"NA","title":"Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-11-06","conditions":"Hepatitis B, Liver Fibrosis","enrollment":186},{"nctId":"NCT01373684","phase":"PHASE4","title":"PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2012-05-25","conditions":"Chronic Hepatitis B","enrollment":90},{"nctId":"NCT02407080","phase":"PHASE1","title":"Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia","status":"COMPLETED","sponsor":"John Mascarenhas","startDate":"2015-04","conditions":"Polycythemia Vera, Essential Thrombocythemia","enrollment":13},{"nctId":"NCT02565719","phase":"PHASE2","title":"REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Replicor Inc.","startDate":"2016-03","conditions":"Chronic Hepatitis B","enrollment":40},{"nctId":"NCT01259856","phase":"PHASE3","title":"Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)","status":"COMPLETED","sponsor":"Ronald Hoffman","startDate":"2011-09","conditions":"High Risk Polycythemia Vera, High Risk Essential Thrombocythemia","enrollment":168},{"nctId":"NCT01604291","phase":"","title":"An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-05-28","conditions":"Hepatitis C, Chronic","enrollment":991},{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT01731158","phase":"PHASE2","title":"Sequential Therapy in Metastatic Renal Cell Carinoma","status":"COMPLETED","sponsor":"Central European Society for Anticancer Drug Research","startDate":"2012-10","conditions":"Metastatic Renal Cell Carcinoma","enrollment":22},{"nctId":"NCT01088659","phase":"PHASE3","title":"A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02-16","conditions":"Hepatitis D, Chronic","enrollment":50},{"nctId":"NCT03733652","phase":"NA","title":"Optimal Treatment for Poor Efficacy of Entecavir in Chronic Hepatitis B Patients","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-11-15","conditions":"Chronic Hepatitis b, Efficacy, Self","enrollment":100},{"nctId":"NCT00037882","phase":"PHASE2","title":"PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2001-02","conditions":"Leukemia, Myeloid, Philadelphia-Positive","enrollment":1},{"nctId":"NCT00038376","phase":"PHASE2","title":"Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1990-05-08","conditions":"Lymphoma, T-Cell, Mycosis Fungoides, Hematologic Neoplasms","enrollment":56},{"nctId":"NCT00019474","phase":"PHASE2","title":"Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"1998-03","conditions":"Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor","enrollment":60},{"nctId":"NCT01544920","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-30","conditions":"Hepatitis C, Chronic","enrollment":737},{"nctId":"NCT01641926","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-26","conditions":"Hepatitis B, Chronic","enrollment":402},{"nctId":"NCT03272009","phase":"PHASE1","title":"Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects","status":"COMPLETED","sponsor":"Enyo Pharma","startDate":"2017-09-21","conditions":"Hepatitis B, Chronic","enrollment":73},{"nctId":"NCT01314261","phase":"PHASE2","title":"Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-03","conditions":"Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection","enrollment":37},{"nctId":"NCT00085436","phase":"PHASE2","title":"DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2003-12","conditions":"Kidney Cancer","enrollment":18},{"nctId":"NCT01609933","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12-18","conditions":"Chronic Hepatitis C","enrollment":32},{"nctId":"NCT02758509","phase":"","title":"Impact of Antiviral Therapy on Gastroesophageal Varices.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-01-01","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":237},{"nctId":"NCT00167583","phase":"PHASE3","title":"Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2004-11","conditions":"Behcet's Disease, Panuveitis, Posterior Uveitis","enrollment":37},{"nctId":"NCT02637999","phase":"PHASE1, PHASE2","title":"Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection","status":"COMPLETED","sponsor":"Hepatera Ltd.","startDate":"2014-02-13","conditions":"Chronic Hepatitis D Infection","enrollment":24},{"nctId":"NCT01679834","phase":"","title":"An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-11-24","conditions":"Hepatitis C, Chronic","enrollment":7500},{"nctId":"NCT02021643","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-12-10","conditions":"Chronic HCV Infection","enrollment":687},{"nctId":"NCT00932971","phase":"PHASE2","title":"HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis","status":"COMPLETED","sponsor":"HepNet Study House, German Liverfoundation","startDate":"2009-06","conditions":"Hepatitis D","enrollment":70},{"nctId":"NCT01439373","phase":"PHASE2","title":"Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-07","conditions":"Hepatitis C, Chronic","enrollment":16},{"nctId":"NCT01351571","phase":"","title":"An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-08","conditions":"Renal Cell Cancer","enrollment":5},{"nctId":"NCT01659567","phase":"","title":"A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-04-06","conditions":"Hepatitis C, Chronic","enrollment":516},{"nctId":"NCT02233075","phase":"PHASE2","title":"REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection","status":"COMPLETED","sponsor":"Replicor Inc.","startDate":"2014-09","conditions":"Chronic HBV Infection (HBeAg Negative)","enrollment":12},{"nctId":"NCT02763969","phase":"PHASE1","title":"Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-05-18","conditions":"Psoriasis","enrollment":357},{"nctId":"NCT00006244","phase":"PHASE2","title":"Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2000-02","conditions":"Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma","enrollment":36},{"nctId":"NCT01648140","phase":"PHASE2","title":"Dose Ranging of GSK2336805 in Combination Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-08-01","conditions":"Hepatitis C, Chronic","enrollment":286},{"nctId":"NCT00204529","phase":"PHASE3","title":"Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2004-10","conditions":"Melanoma","enrollment":901},{"nctId":"NCT01153919","phase":"PHASE2","title":"Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2010-06-30","conditions":"Hepatitis C Infection, Thrombocytopenia","enrollment":27},{"nctId":"NCT01697501","phase":"PHASE3","title":"A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-11-08","conditions":"Hepatitis B, Chronic","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":381,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Roferon"],"phase":"phase_3","status":"active","brandName":"Interferon-alpha2a","genericName":"Interferon-alpha2a","companyName":"Royal Marsden NHS Foundation Trust","companyId":"royal-marsden-nhs-foundation-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interferon-alpha2a activates the innate immune system by binding to interferon-alpha receptors on immune cells and tumor cells, enhancing antiviral and anti-tumor immune responses. Used for Metastatic melanoma, Chronic myeloid leukemia (CML), Follicular lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}